Every year, millions of people get a broken bone. While some fractures may only need a splint, cast, brace or sling for their bone to heal, numerous cases need more sophisticated and effective treatments such as surgeries.
Today, bone fractures are mostly treated with invasive surgical insertion of metal implants, which lack adaptability and often lead to serious post-surgical complications. This results in prolonged hospital stays, patient suffering, and long-term disabilities, placing a heavy burden on healthcare systems.
The issue is particularly severe for hand fractures, which account for 24% of all fractures and represent the most expensive orthopaedic injury due to loss of productivity. Worryingly, metal plate fixation for finger fractures leads to complications in up to 64% of cases, with over 40% requiring reoperation, and just 8% of patients regaining full hand function.
In light of this situation, Biomedical Bonding (BMB) has developed Bonevolent®, a first-in-class, blue light-curable biomaterial platform for fracture repair. Their patented technology enables the formation of a bone-like, smooth, and highly biocompatible plate, which perfectly adapts to the bone’s shape, ensuring optimal fracture reduction. This minimally invasive approach eliminates the common risks of metal plates, significantly reducing complications, reoperations, and patient discomfort.
Strata has been working with Biomedical Bonding for several years now, supporting them on their journey to obtain public funding.
How did Biomedical Bonding journey begin?
Biomedical Bonding (BMB) was founded in 2008 with a mission to advance hard-tissue repair by developing high-performance materials with outstanding biocompatibility. The Bonevolent® technology and the AdhFix product are the result of over 15 years of intensive R&D, carried out in close collaboration with leading academic partners and surgeons.
“At BMB, our mission is to deliver innovative, personalised implantable solutions that not only enhance patient safety but also save costs and resources for healthcare systems and society”.
What makes Biomedical bonding innovation so disruptive?
Unlike traditional metal plates, BMB patented technology enables the formation of bone-like plates that are smooth, bioinert, and perfectly shaped to match the natural contours of the bone, ensuring optimal fracture reduction.
“Our unique composite offers exceptional biocompatibility, making personalised implants a reality for the first time, tailored to each individual fracture”.
Bonevolent® introduces a groundbreaking approach to bone fracture repair. Its features provide immediate stability and unparalleled bioinert behaviour, reducing the complications often associated with metal plates, such as irritation, tissue adhesions, internal scarring, and patient discomfort.
“Our first product, AdhFix, will address five key indications for hand, wrist, foot, face, and cranium fractures, with hand fractures as our primary target indication”.
How would you describe the team you’ve been working with in these applications?
BMB has worked with Strata Team for several years
“You have good people that know what type of questions typically are asked, and this is one thing that we will appreciate further in the future”-said Dr. Malkoch.
And what can you say about this collaboration with Strata?
“A feature that you have is that there is more than one consultant that is actually supporting, so there’s always people coming from different angles. It is important that a lot of the team members are still there, supporting and organising the proposals, so this is also something that one has to consider, that you feel that there is stability in the organization”-Dr. Malkoch shared.
About the author of this post
Sara Gavidia
Marketing & Communications Manager
E-learning Specialist
LinkedIn
sara.gavidia@strata.team
Hello! I’m Sara 👋🏻 I’m the Lead content editor at Strata. We want to thank all our lovely clients for sharing their insightgul and inspiring stories with all of us. Feel free to explore and read all of them!
